Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01705483 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies
A Phase 1 study, sponsored by Astellas Pharma Global Development.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT01705483 is a Phase 1 study that was terminated before completion, run by Astellas Pharma Global Development. The registered enrollment target is 21 participants.
The verdict
NCT01705483, a Phase 1 study, was terminated before completion, sponsored by Astellas Pharma Global Development.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability and pharmacokinetics of ASP9853 combined with docetaxel or with paclitaxel in subjects with advanced non-hematologic malignancies.
Interventions
- DRUG Docetaxel
- DRUG Paclitaxel
- DRUG ASP9853
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2012-08-28 |
| Est. Completion | 2014-06-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01705483
The ClinicalTrials.gov registry entry for NCT01705483 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT01705483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01705483 about?
NCT01705483 is a clinical study titled "A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies". The purpose of this study is to determine the safety and tolerability and pharmacokinetics of ASP9853 combined with docetaxel or with paclitaxel in subjects with advanced non-hematologic malignancies.
What is the current status of trial NCT01705483?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2012-08-28. Estimated completion is 2014-06-11.
What interventions are being tested in trial NCT01705483?
The interventions under investigation include: Docetaxel (DRUG), Paclitaxel (DRUG), ASP9853 (DRUG).
Who is sponsoring clinical trial NCT01705483?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.